Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 7/20 | 0.47 |
| ▸ | ITGAV | P06756 | 7/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.47 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.45 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 12/20 | 0.38 |
| ▸ | PPARA | Q07869 | 3/20 | 0.36 |
| ▸ | PPARG | P37231 | 4/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6419206 | 0.84 | ITGB3 (0.53) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL6787868 | 0.82 | ITGB3 (0.66) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL2050052 | 0.82 | ITGB3 (0.52) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL6423446 | 0.81 | ITGB3 (0.71) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL7171868 | 0.81 | ITGB3 (0.69) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL7172734 | 0.81 | ITGB3 (0.69) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL7449605 | 0.81 | ITGB3 (0.69) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL6419530 | 0.79 | ITGB3 (0.35) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL7171786 | 0.78 | ITGB3 (0.55) | ITGB3ITGAVITGA2BITGB1ITGB5 | |
| SCHEMBL7171856 | 0.77 | ITGB3 (0.57) | ITGB3ITGAVITGA2BITGB1ITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082559-A1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082559-A1 | Vitronectin receptor antagonists | VCAM1, GPR174, ADGRF1 | ITGB3 131/4885ITGAV 302/4885ITGA2B 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.